Thyroid carcinoma in nodules with Thy3 cytology: Retrospective study in a district general hospital
Keywords:
thyroid, thyroid cancer, FNAC, Thy3 cytology, hemithyroidectomyAbstract
Background and Aim
Thyroid cancer is the most common malignant endocrine tumour. Fine needle aspiration cytology plays an important role in diagnosis of these tumours. The aim of the current study was to determine thyroid cancer risk for Thy3 cytology over a seven-year period from 2015 to 2021 at Royal Lancaster Infirmary, UK.
Methods
206 medical records with Thy3 cytology were retrospectively reviewed from January 2015 to December 2021. Patients were classified into two groups: Thy3a and Thy3f. Histopathology reports were compared with cytology reports in order to determine malignancy rates.
Results
18.9% of male patients and 23% of female patients had a malignant histology The average overall malignancy rate was 22.2%. More specifically, 22% of Thy3a and 22.4% of Thy3f were malignant. 22 patients eventually underwent completion thyroidectomy of which 6 patients had malignancy in the contralateral lobe.
Conclusion
Malignancy rates at our center was lower as compared to the national data rates.
References
UK CR. Thyroid cancer incidence statistics. http://www.cancerrese archuk.org/health profession al/cancer-statistics/ statistics-by-cancer-type/thyroid-cancer/incidence. March 2018.
Cross P, Giles T, Johnson S, et al. Guidance on the Reporting of Thyroid Cytology Specimens. London. Royal College of Pathologists; 2016. www.rcpath.org/uploads/assets/7d693ce4-0091-4621-97f79e2a0d1034d6/g089_guidance_on_reporting_of_thyroid_cytology_specimens.pdf
Rcr.ac.uk. 2022. Audit of thyroid U-classification and subsequent fine needle aspiration cytology. The Royal College of Radiologists. https://www.rcr.ac.uk/audit/audit-thyroid-u-classification-and-subsequent-fine-needle-aspiration-cytology.
Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol. 2010;118(1):17-23.
Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol. 2014;81(1):1-122.
6. Aspinall S. Sixth national Audit Report. The British Association on Endocrine and Thyroid Surgeons; 2021. www.baets.org.uk/wp-content/uploads/BAETS-Sixth-Audit-Report-FINAL.pdf
Nair D, Kandiah S, Rourke T, Corbridge R, Nagala S. Malignancy rates and initial management of Thy3 thyroid nodules in a district general hospital: The 'Reading' experience. Endocrinol Diabetes Metab. 2021;4(3):e00243.
Ho AS, Sarti EE, Jain KS, et al. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid. 2014;24(5):832-839.
Alexander V, Rudd J, Walker D, et al. Thy 3F and 3a malignancy rate, a multisite regional retrospective case series. Ann R Coll Surg Engl. 2018;100(7):545-550.
Hassanain M, Wexler M. Conservative management of well-differentiated thyroid cancer. Can J Surg. 2010;53(2):109-118.
Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38(1):68-79
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma:
A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncology. 2016;2(8):1023-1029.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Chirag Pereira
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
